Other
Stem Cell Transplantation
0
Pipeline Programs↗
7
Active Trials↗
1
Companies Involved↗
Stem Cell Transplantation is an early-stage landscape with 0 programs across 1 company. The most active players are Kiadis Pharma.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
97
clinical trials
Completed57 · 59%
Terminated18 · 19%
Unknown status11 · 11%
Recruiting4 · 4%
Withdrawn4 · 4%
Active, not recruiting2 · 2%
Other1 · 1%
Clinical Trials
Trial Activity
97 trials
Stem Cell Transplantation in Crohn's Disease
Recruiting·—·Phase 1/2·NCT04224558·15 enrolled
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
Recruiting·—·Phase 1/2·NCT07438067·18 enrolled
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Active, not recruiting·—·Phase 2·NCT01067287·35 enrolled
Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00426517·48 enrolled
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies
Completed·—·N/A·NCT00426205·28 enrolled
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
Completed·—·Phase 2·NCT00144703·55 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)